| Identification | Back Directory | [Name]
1H-Pyrrole-2-carboxamide, N-[(1S)-2-amino-1-[4-(hydroxymethyl)-2-thiazolyl]ethyl]-5-[3-fluoro-4-(trifluoromethyl)phenyl]- | [CAS]
2234273-72-2 | [Synonyms]
1H-Pyrrole-2-carboxamide, N-[(1S)-2-amino-1-[4-(hydroxymethyl)-2-thiazolyl]ethyl]-5-[3-fluoro-4-(trifluoromethyl)phenyl]- | [Molecular Formula]
C18H16F4N4O2S | [MOL File]
2234273-72-2.mol | [Molecular Weight]
428.4 |
| Chemical Properties | Back Directory | [Boiling point ]
638.0±55.0 °C(Predicted) | [density ]
1.481±0.06 g/cm3(Predicted) | [storage temp. ]
4°C, away from moisture and light | [form ]
Solid | [pka]
5.67±0.46(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Description]
NBD-14189 is a potent HIV-1 entry antagonist with an IC50 of 89 nM against the HIV-1HXB2 pseudovirus. NBD-14189 binds to HIV-1 gp120 and shows potent antiviral activity (EC50<200 nM)[1][2]. NBD-14189 has anti-HIV-1 activity (IC50=0.089 μM) and cytotoxicity (CC50=21.9 μM) in single-cycle (TZM-bl cells) assays. NBD-14189 has anti-HIV-1 activity (IC50=0.18 μM) and cytotoxicity (CC50=22.1 μM) in multi-cycle (MT-2 cells) assays[1].
NBD-14189 (0-50 μM) prevents HIV-1 mediated cell-cell fusion with an IC50 of 9.4 μM in indicator cells TZM-bl cells were cocultured with Env- and Tat-expressing HL2/3 cells[1].
NBD-14189 shows weak or no inhibition of the hERG current, with an IC50 of 3.0 μM, respectively[1].
| [Uses]
NBD-14189 is a potent HIV-1 entry antagonist with an IC50?of 89 nM against the HIV-1HXB2?pseudovirus. NBD-14189 binds to HIV-1 gp120 and shows potent antiviral activity (EC50<200 nM)[1][2]. | [IC 50]
HIV-1 | [References]
[1] Francesca Curreli, et al. Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120. Eur J Med Chem. 2018 Jun 25;154:367-391. DOI:10.1016/j.ejmech.2018.04.062
[2] Natalie Losada, et al. HIV-1 gp120 Antagonists Also Inhibit HIV-1 Reverse Transcriptase by Bridging the NNRTI and NRTI Sites. J Med Chem. 2021 Nov 25;64(22):16530-16540. DOI:10.1021/acs.jmedchem.1c01104 |
|
|